1. Home
  2. INTS vs CGTX Comparison

INTS vs CGTX Comparison

Compare INTS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • CGTX
  • Stock Information
  • Founded
  • INTS 2012
  • CGTX 2007
  • Country
  • INTS United States
  • CGTX United States
  • Employees
  • INTS N/A
  • CGTX N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • INTS Health Care
  • CGTX Health Care
  • Exchange
  • INTS Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • INTS 33.4M
  • CGTX 30.0M
  • IPO Year
  • INTS 2023
  • CGTX 2021
  • Fundamental
  • Price
  • INTS $2.20
  • CGTX $0.64
  • Analyst Decision
  • INTS Strong Buy
  • CGTX Strong Buy
  • Analyst Count
  • INTS 3
  • CGTX 6
  • Target Price
  • INTS $8.50
  • CGTX $8.30
  • AVG Volume (30 Days)
  • INTS 41.6K
  • CGTX 945.7K
  • Earning Date
  • INTS 03-13-2025
  • CGTX 03-25-2025
  • Dividend Yield
  • INTS N/A
  • CGTX N/A
  • EPS Growth
  • INTS N/A
  • CGTX N/A
  • EPS
  • INTS N/A
  • CGTX N/A
  • Revenue
  • INTS N/A
  • CGTX N/A
  • Revenue This Year
  • INTS N/A
  • CGTX N/A
  • Revenue Next Year
  • INTS N/A
  • CGTX N/A
  • P/E Ratio
  • INTS N/A
  • CGTX N/A
  • Revenue Growth
  • INTS N/A
  • CGTX N/A
  • 52 Week Low
  • INTS $1.50
  • CGTX $0.34
  • 52 Week High
  • INTS $5.94
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • INTS 54.20
  • CGTX 43.76
  • Support Level
  • INTS $2.00
  • CGTX $0.60
  • Resistance Level
  • INTS $2.37
  • CGTX $0.82
  • Average True Range (ATR)
  • INTS 0.31
  • CGTX 0.06
  • MACD
  • INTS -0.00
  • CGTX -0.02
  • Stochastic Oscillator
  • INTS 48.24
  • CGTX 18.56

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: